Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Pentixapharm Holding AG's Enterprise Value is €-2.67 Mil.
Pentixapharm Holding AG's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 was €-14.62 Mil. Therefore, Pentixapharm Holding AG's EV-to-FCF for today is 0.18.
The historical rank and industry rank for Pentixapharm Holding AG's EV-to-FCF or its related term are showing as below:
FRA:PTP'
s EV-to-FCF Range Over the Past 10 Years
Min: -9.66 Med: -3.04 Max: 0.18
Current: 0.18
During the past 5 years, the highest EV-to-FCF of Pentixapharm Holding AG was 0.18. The lowest was -9.66. And the median was -3.04.
FRA:PTP's EV-to-FCF is ranked better than 92.66% of 327
companies
in the Biotechnology industry
Industry Median: 18.51
vs FRA:PTP: 0.18
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Pentixapharm Holding AG (FRA:PTP) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Pentixapharm Holding AG's PE Ratio (TTM) for today is calculated as:
Pentixapharm Holding AG's share price for today is €1.85.
Pentixapharm Holding AG's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.585.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Pentixapharm Holding AG's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pentixapharm Holding AG EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Pentixapharm Holding AG's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Pentixapharm Holding AG's EV-to-FCF falls into.
Pentixapharm Holding AG's current Enterprise Value is €-2.67 Mil.
Pentixapharm Holding AG's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-14.62 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pentixapharm Holding AG (FRA:PTP) has a EV-to-FCF of 0.18 as of Aug. 16, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Pentixapharm Holding AG and its competitors. According to the industry distribution chart, Pentixapharm Holding AG ranks #24 out of 327 companies in the Biotechnology industry, placing it in the top 7.3%.
Is Pentixapharm Holding AG's EV-to-FCF too high?
Pentixapharm Holding AG's current EV-to-FCF is 0.18. The Biotechnology industry median EV-to-FCF is 18.51. Pentixapharm Holding AG's value of 0.18 is 99% below this industry median. Based on the distribution chart, Pentixapharm Holding AG ranks #24 out of 327 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Pentixapharm Holding AG has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Pentixapharm Holding AG's EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Pentixapharm Holding AG ranks #24 out of 327 companies for EV-to-FCF. This places Pentixapharm Holding AG in the top 7% of its industry — outperforming the majority of peers. The industry median EV-to-FCF is 18.51. Pentixapharm Holding AG's value of 0.18 is 99% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 18.51, based on 327 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pentixapharm Holding AG's current EV-to-FCF of 0.18 is 99% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Pentixapharm Holding AG and its competitors. For the Biotechnology industry, the median EV-to-FCF is 18.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pentixapharm Holding AG's current EV-to-FCF is 0.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pentixapharm Holding AG stock overvalued right now?
Pentixapharm Holding AG (FRA:PTP) has a current EV-to-FCF of 0.18. The current EV-to-FCF is 0.18 and 99% below the Biotechnology industry median of 18.51. Pentixapharm Holding AG's overall GF Score™ is 20/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Pentixapharm Holding AG (FRA:PTP), the current EV-to-FCF is 0.18 as of Aug. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Pentixapharm Holding AG is a clinical-stage biopharmaceutical company active in the field of research and development of radiopharmaceuticals for diagnostic and therapeutic applications. Radiopharmaceuticals are medical substances containing radioactive elements used in nuclear medicine to diagnose or treat diseases. Its clinical pipeline encompasses PentixaTher, a Yttrium-90 based therapeutic against non-Hodgkin lymphomas (NHL), and PentixaFor, a Gallium-68-based companion diagnostic. Its Pipeline products include: Pentixa Ther, PT-002, PentixaFor, PT-001, PentixaFor, PT-001, PT-00X, GT-001, GT-002, GT-005, GT-008, and GT-00X.
20GF Score
Get the complete analysis for FRA:PTP
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:PTP has been successfully added to your 
